Gilead goes all in on its Arcus alliance, paying $725M cash for rights to a slate of cancer drugs. And there’s no room for failure

Gilead is going all in — hook, line and sinker — on its oncology alliance with Arcus. And they are going for broke. The big biotech unveiled a deal that now delivers $725 million in opt-in payments covering the clinical development programs for Arcus, ranging from their closely watched anti-TIGIT…

...

Click to view original post